By Doug Macron
Mira Dx this week announced that it has licensed from Yale University technology related to microRNA-disrupting genetic variants that can be used to predict a patient's risk of developing triple negative breast cancer.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now. Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
In Science this week: gene regulation changes linked to human brain evolution, and more.
The New York Stem Cell Foundation's Initiative on Women in Science and Engineering working group presents seven strategies to promote gender equality in the sciences.
Researchers link a genetic variation to the ability to quickly process arsenic in people living in the Andes Mountains.
A small portion of pregnant women who've undergone non-invasive prenatal testing have found out from the test that they have cancer.